Generics Bulletin is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Henlius Doses First Patient In China For Ophthalmic Bevacizumab

Follows US FDA Approving Henlius’ Investigational New Drug Application

Executive Summary

Chinese firms Shanghai Henlius Biotech and Essex Bio-Technology have announced a key milestone in their Chinese Phase I clinical study for the HLX04-O biosimilar bevacizumab candidate to treat wet age-related macular degeneration.

You may also be interested in...



Henlius Bevacizumab Trials Results Get International Recognition

China’s Henlius has received international recognition of Phase I and III clinical trial results for its bevacizumab biosimilar, HLX04, providing “strong evidence for the efficacy and safety similarity between HLX04 and the reference bevacizumab.” The company has submitted its NDA for the product to the NMPA for various indications.

Ophthalmic Bevacizumab Reaches Critical Review Stage In EU

The sponsor of what could become the EU’s first approved ophthalmic formulation of bevacizumab needs to address outstanding issues raised by the European Medicines Agency about its filing.

Henlius Finds Global Partner For Ophthalmic Bevacizumab

Shanghai Henlius Biotech has struck a co-development and licensing deal with fellow Chinese firm Essex Bio-Technology for biosimilar bevacizumab to treat ophthalmic diseases.

Topics

Related Companies

UsernamePublicRestriction

Register

GB151108

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel
;